Pfizer is inviting applications for its Transthyretin Cardiac Amyloidosis Fellowship, which supports both established and emerging Amyloid Centers of Excellence.
To that end, the program provides up to $240,000 in support of fellowship programs for cardiologists focused on clinical practice, research, and education, with the aim of furthering the understanding of transthyretin cardiac amyloidosis. Fellowship programs must include independent research and a strong mentoring program; clinical training may be included in the program but is not required. Examples of independent research include observational studies and outcomes research studies where the primary focus is the scientific understanding of disease, and the use of screening tools and their impact on improvement of patient health. Examples of clinical training include educational time with an interdisciplinary team in review of case examples and relevant didactic training, as well as the use of tools for improvement in patient health with respect to specific therapeutic areas or conditions.
Eligible applicants include accredited, U.S.-based academic institutions. Institutions must ensure that any fellow who receives grant funds is a U.S. worker (U.S. citizen, permanent resident, refugee, or asylee), or hold an appropriate non-immigrant visa status authorizing employment in the U.S.
See the Pfizer website for complete program guidelines and application instructions.